Gilead Sciences (GILD -1.1%) has initiated a U.S. Phase 1a clinical trial evaluating an inhalable formulation of antiviral remdesivir in 60 healthy volunteers between the ages of 18 and 45.
The company says an inhalable version may enable more targeted and accessible administration in non-hospitalized COVID-19 patients and lower systemic exposure to the drug.
The intravenous formulation remains the only medicine approved in the U.S. for emergency use in hospitalized patients, receiving the FDA nod on May 1.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.